Genomic Atlas of Human Plasma Proteome Publicized
By LabMedica International staff writers Posted on 26 Jun 2018 |

Image: Duolink proximity ligation assay technology extends the capabilities of traditional protein techniques (Photo courtesy of Olink Proteomics).
Although plasma proteins have important roles in biological processes and are the direct targets of many drugs, the genetic factors that control inter-individual variation in plasma protein levels are not well understood.
Bringing in expression quantitative trait locus (QTL) and protein QTL data, biological pathway clues, drug database insights, and variants identified in prior genome-wide association studies, a team of scientists subsequently searched for plasma proteins contributing to common conditions, such as inflammatory bowel disease, as well as for potential drugs for altering these pathways.
A large team of scientists collaborating with those at the University of Cambridge (Cambridge, UK) characterized the genetic architecture of the human plasma proteome in healthy blood donors. The study involved about 50,000 participants, and the team systematically quantified levels for thousands of proteins in plasma samples from 3,301 seemingly healthy, genotyped individuals. With these data, they uncovered more than 1,900 interactions between almost 800 genomic regions and nearly 1,500 proteins.
The scientists used the SOMAscan, an aptamer-based multiplex protein assay. They quantified plasma levels of 3,622 proteins in blood samples from 3,301 healthy donors. They set those proteome data alongside genetic profiles for the participants, searching for associations between plasma proteins and 10.6 million autosomal SNPs that were imputed or directly assessed using Affymetrix Axiom UK Biobank arrays. The team's analysis uncovered 1,927 associations involving 1,478 proteins and 764 regions in the genome. Most of those associations, 89%, had not been described previously.
The team noted that 502 of the protein-associated loci appeared to act locally, or in cis, while 228 had trans effects on plasma proteins. The remaining 34 loci appeared to have both cis and trans protein interactions. They validated 106 of 163 proposed protein QTLs using an Olink protein assay (Uppsala, Sweden; www.olink.com) on samples from another 4,998 individuals, noting that the cis pQTLs appeared more apt to replicate than those involving longer-range trans interactions. After exploring the overlap between the proposed pQTLs and expression QTLs reported in the past, the investigators incorporated information from prior genome-wide association study.
The authors concluded that by linking genetic factors to diseases via specific proteins, their analyses highlight potential therapeutic targets, opportunities for matching existing drugs with new disease indications, and potential safety concerns for drugs under development. The study was published on June 6, 2018, in the journal Nature.
Related Links:
University of Cambridge
Bringing in expression quantitative trait locus (QTL) and protein QTL data, biological pathway clues, drug database insights, and variants identified in prior genome-wide association studies, a team of scientists subsequently searched for plasma proteins contributing to common conditions, such as inflammatory bowel disease, as well as for potential drugs for altering these pathways.
A large team of scientists collaborating with those at the University of Cambridge (Cambridge, UK) characterized the genetic architecture of the human plasma proteome in healthy blood donors. The study involved about 50,000 participants, and the team systematically quantified levels for thousands of proteins in plasma samples from 3,301 seemingly healthy, genotyped individuals. With these data, they uncovered more than 1,900 interactions between almost 800 genomic regions and nearly 1,500 proteins.
The scientists used the SOMAscan, an aptamer-based multiplex protein assay. They quantified plasma levels of 3,622 proteins in blood samples from 3,301 healthy donors. They set those proteome data alongside genetic profiles for the participants, searching for associations between plasma proteins and 10.6 million autosomal SNPs that were imputed or directly assessed using Affymetrix Axiom UK Biobank arrays. The team's analysis uncovered 1,927 associations involving 1,478 proteins and 764 regions in the genome. Most of those associations, 89%, had not been described previously.
The team noted that 502 of the protein-associated loci appeared to act locally, or in cis, while 228 had trans effects on plasma proteins. The remaining 34 loci appeared to have both cis and trans protein interactions. They validated 106 of 163 proposed protein QTLs using an Olink protein assay (Uppsala, Sweden; www.olink.com) on samples from another 4,998 individuals, noting that the cis pQTLs appeared more apt to replicate than those involving longer-range trans interactions. After exploring the overlap between the proposed pQTLs and expression QTLs reported in the past, the investigators incorporated information from prior genome-wide association study.
The authors concluded that by linking genetic factors to diseases via specific proteins, their analyses highlight potential therapeutic targets, opportunities for matching existing drugs with new disease indications, and potential safety concerns for drugs under development. The study was published on June 6, 2018, in the journal Nature.
Related Links:
University of Cambridge
Latest Molecular Diagnostics News
- Novel Autoantibody Against DAGLA Discovered in Cerebellitis
- Blood Test Could Identify Patients at Risk for Severe Scleroderma
- Gene-Based Blood Test Accurately Predicts Tumor Recurrence of Advanced Skin Cancer
- Rapid Blood Test Identifies Pre-Symptomatic Patients with Parkinson’s Disease
- Blood Test for Early Alzheimer's Detection Achieves Over 90% Accuracy
- RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms
- First Of Its Kind Test Uses microRNAs to Predict Toxicity from Cancer Therapy
- Novel Cell-Based Assay Provides Sensitive and Specific Autoantibody Detection in Demyelination
- Novel Point-of-Care Technology Delivers Accurate HIV Results in Minutes
- Blood Test Rules Out Future Dementia Risk
- D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism
- New Biomarkers to Improve Early Detection and Monitoring of Kidney Injury
- Chemiluminescence Immunoassays Support Diagnosis of Alzheimer’s Disease
- Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury
- Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression
- Simple DNA PCR-Based Lab Test to Enable Personalized Treatment of Bacterial Vaginosis
Channels
Clinical Chemistry
view channel
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more
New Error-Corrected Method to Help Detect Cancer from Blood Samples Alone
"Liquid biopsy" technology, which relies on blood tests for early cancer detection and monitoring cancer burden in patients, has the potential to transform cancer care. However, detecting the mutational... Read more
"Metal Detector" Algorithm Hunts Down Vulnerable Tumors
Scientists have developed an algorithm capable of functioning as a "metal detector" to identify vulnerable tumors, marking a significant advancement in personalized cancer treatment. This breakthrough... Read more
Novel Technique Uses ‘Sugar’ Signatures to Identify and Classify Pancreatic Cancer Cell Subtypes
Pancreatic cancer is often asymptomatic in its early stages, making it difficult to detect until it has progressed. Consequently, only 15% of pancreatic cancers are diagnosed early enough to allow for... Read moreTechnology
view channel
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more